PIK3CA and breast carcinoma: The optimal endocrine combination with PI3K inhibition in cells resistant to estrogen deprivation is a critical consideration since the overwhelming majority of patients with advanced breast cancer have already been treated with an aromatase inhibitor in the adjuvant setting.